

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Peijia Medical Limited**

**沛嘉醫療有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 9996)**

**VOLUNTARY ANNOUNCEMENT  
FIRST PATIENT IMPLANT IN THE U.S. EARLY  
FEASIBILITY STUDY FOR THE GeminiOne®  
TRANSCATHETER EDGE-TO-EDGE REPAIR SYSTEM**

This announcement is made by Peijia Medical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders of the Company and potential investors with updated information in relation to the latest business and new product development progress of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that the first patient implant in the U.S. Food and Drug Administration (“**FDA**”) Early Feasibility Study (“**EFS**”) for the GeminiOne® Transcatheter Edge-to-Edge Repair (“**TEER**”) system has been successfully completed. The procedure was performed by Professor Saibal Kar, Director of Structural Heart Disease Interventions and Clinical Research at Los Robles Regional Medical Center (part of HCA Healthcare), and Clinical Professor of Medicine at the David Geffen School of Medicine at University of California, Los Angeles.

**THE COMPANY MAY NOT BE ABLE TO ULTIMATELY DEVELOP AND MARKET GeminiOne® TEER SYSTEM SUCCESSFULLY. SHAREHOLDERS OF THE COMPANY AND POTENTIAL INVESTORS ARE ADVISED TO EXERCISE DUE CARE WHEN DEALING IN THE SHARES OF THE COMPANY.**

By order of the Board  
**Peijia Medical Limited**  
**Dr. Yi ZHANG**  
*Chairman and Executive Director*

Hong Kong, April 9, 2026

*As of the date of this announcement, the Board comprises Dr. Yi ZHANG, Mrs. Ping Ye ZHANG and Ms. Hong YE as executive Directors, Mr. Jifeng GUAN, Mr. Fei CHEN, Mr. Jun YANG as non-executive Directors, and Dr. Stephen Newman OESTERLE, Mr. Robert Ralph PARKS, Mr. Wai Ming YIP, Mr. Huacheng WEI as independent non-executive Directors.*